Novo Nordisk launches online contest for insulin pen users
PRINCETON, N.J. Novo Nordisk is asking diabetics to show off how they flex — their insulin pens.
In an effort to change the way people think about taking insulin, Novo Nordisk has launched an online photo contest, “Where Have You Flexed,” for patients who use Levemir FlexPen, NovoLog FlexPen and NovoLog Mix 70/30 FlexPen. Patients can visit WhereHaveYouFlexed.com to submit photos they have taken in unique locations with their FlexPen.
“’Where Have You Flexed’ is an exciting way for people using the FlexPen to show first-hand how they can conveniently take their insulin on-the-go,” said Camille Lee, VP diabetes marketing for Novo Nordisk. “Through the interactive voting function on the site, we look forward to seeing which entries have the biggest impact within the diabetes community and hope that people still taking insulin with a vial and syringe will be inspired to talk to their doctor about FlexPen.”
Also on the WhereHaveYouFlexed.com site, viewers can watch video with stories from Firestone Indy Lights racecar driver Charlie Kimball, who uses the Levemir FlexPen to help manage his diabetes. The grand prize winner of the Where Have You Flexed contest (determined by a panel of judges and consumer votes) will receive a trip for two to the Firestone Indy Lights championship in Miami on Oct. 2 to see Kimball race, or an elliptical trainer exercise machine delivered to their home. Second and third place winners will receive exercise equipment for their home, while anyone who registers to vote on the site will be entered in a random drawing to win one of five iPod touch portable music players.
“As a professional racing driver, I get to ‘flex’ all over the country — including on the racetrack,” said Kimball, who drives the No. 26 Levemir FlexPen car and is the only licensed racer with Type 1 diabetes in the history of the Indy Racing League. “I’m looking forward to seeing the photos of where other patients with diabetes use their FlexPen and sharing videos of my experiences on the road.”
Everlast ProLine seeks to maximize workout benefits for athletes
NEW YORK Everlast Sports Nutrition is launching a collection of nutrition products specifically created for the dedicated athlete, called Everlast ProLine.
The collection features advanced nutrients, including natural sweeteners and natural flavors, and includes products that maximize workout benefits while managing weight and recovery.
Developed by a team of industry professionals that includes nutritionists, athletes and fitness-enthusiasts, the ProLine was created to deliver scientifically validated ingredients in proven sports nutrition products for optimum athletic performance. Formulas were carefully chosen, tested and combined to support optimal strength, energy and focus.
Everlast Sports Nutrition ProLine will begin shipping in May.
Study: Vitamin B may decrease kidney function in diabetic nephropathy patients
NEW YORK Patients with a kidney disease caused by diabetes that receive high-dose vitamin B therapy are more likely to have decreased kidney function and an increased risk of heart attack and stroke, a new study found.
Published in the Apr. 28 issue of the Journal of the American Medical Association, Andrew House, M.D., of the University of Western Ontario, and J. David Spence, M.D., of the Robarts Research Institute, London, Ontario, and colleagues conducted a study to examine whether B-vitamin therapy would slow the progression of diabetic nephropathy and prevent vascular events in 238 patients with Type 1 or 2 diabetes. Data taken from patients in the randomized, placebo-controlled trial between May 2001 and May 2007 found the measure of kidney function — radionuclide glomerular filtration rate, or GFR — rapidly decreased in those who consumed vitamin B6 and B12, between baseline and 36 months, compared with the placebo group. Additionally, the researchers found that risk of such cardiovascular events as heart attack, stroke, revascularization, and all-cause mortality, doubled in the B-vitamin group.
Meanwhile, House, Spence and colleagues also added that they tested the patients’ levels of homocysteine, a naturally occurring amino acid found in blood plasma. While high levels of homocysteine are more likely to cause heart attack and other diseases, the researchers noted that participants in the B-vitamin group had an average decrease while participants in the placebo group had an average increase. This result, the authors concluded, should not necessarily be a guide for those interested in testing this theory outside of a clinical trial.
"Given the recent large-scale clinical trials showing no treatment benefit, and our trial demonstrating harm, it would be prudent to discourage the use of high-dose B vitamins as a homocysteine-lowering strategy outside the framework of properly conducted clinical research," the authors concluded.